Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Reaction Biology Top-Ranked in Kinase Profiling Survey

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
RBC also ranked highly on technical support and data quality.

Reaction Biology Corporation ("RBC") has announced that it has received the highest number of positive ratings in a recent industry survey.

HTStec, a UK-based technical research firm, surveyed 78 research labs around the globe for its Kinase Profiling Trends 2013 report. The labs included large pharmas, biotechs, university and non-profit labs.

Survey participants were asked to rate the 16 top kinase profiling outsource providers on eight different attributes.

The provider with the highest number of positive ratings was RBC, which came in number one on customer service, turnaround time, and low cost.

RBC also ranked as the most-used provider to the industry, rising from fifth place in the same survey taken in 2010.

“We are very pleased with this validation of our efforts to provide the widest coverage of the kinome, with a gold standard activity assay,” said Dr. Haiching Ma, Chief Science Officer of RBC.

Dr. Ma continued, “Eighty-eight percent of all pharmas in the survey preferred activity-based assays, and RBC’s radiolabeled HotSpot assay now provides high-quality reproducible data on 457 kinases.”

The survey estimated that RBC had the largest share of the $34 million kinase profiling market.

Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With more than 450 kinases, RBC’s coverage of the kinome is the broadest in the industry.

Using its proprietary HotSpotSM technology and other innovations, RBC is expanding its already substantial production of epigenetic regulatory enzymes.

RBC has provided its services to over 300 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reaction Biology and Cisbio Sign Distribution Agreement
Agreement will see Cisbio distribute Reaction Biology's epigenetic proteins.
Friday, January 17, 2014
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos